# Dyne (DYN) — News

DYN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/dyn/news

## Recent headlines

- [Dyne Therapeutics, Inc.: H.C. Wainwright cuts target price to $32 from $50](https://www.ainvest.com/news/dyne-therapeutics-wainwright-cuts-target-price-32-50-2609) — AInvest Wire, Sep 30, 2026
  H.C. Wainwright & Co. has revised its price target for Dyne Therapeutics, Inc. (NASDAQ: DYN) from $50 to $32, reflecting a 36% reduction in its projected share value [1]. The adjustment follows a reassessment of the company’s near-term clinical and commercial prospects, though the firm has not…
- [Dyne Therapeutics expects topline data from Achieve Rec in Q1 2027 with primary endpoint vhot at 6 months](https://www.ainvest.com/news/dyne-therapeutics-expects-topline-data-achieve-rec-q1-2027-primary-endpoint-vhot-6-months-2609) — AInvest Wire, Sep 29, 2026
  Dyne Therapeutics, Inc. (Nasdaq: DYN) has announced that topline data from the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, DYNE-101) in myotonic dystrophy type 1 (DM1) is expected in the first quarter of 2027. The primary endpoint for…
- [Dyne Therapeutics, - Reports improvement at 6 months in vhot with Z-basivarsen in DM1](https://www.ainvest.com/news/dyne-therapeutics-reports-improvement-6-months-vhot-basivarsen-dm1-2609) — AInvest Wire, Sep 29, 2026
  Dyne Therapeutics is conducting a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy type 1 (DM1) under the trial identifier NCT07486934. The trial, which began on May 14, 2026, is expected to…
- [Dyne Therapeutics announces additional one-year clinical data from phase 1/2 achieve trial of Z-basivarsen (Dyne-101) for myotonic dystrophy type 1 (DM1)](https://www.ainvest.com/news/dyne-therapeutics-announces-additional-year-clinical-data-phase-1-2-achieve-trial-basivarsen-dyne-101-myotonic-dystrophy-type-1-dm1-2609) — AInvest Wire, Sep 29, 2026
- [Sarepta Therapeutics down 11.4%, Dyne Therapeutics down 22%](https://www.ainvest.com/news/sarepta-therapeutics-11-4-dyne-therapeutics-22-2609) — AInvest Wire, Sep 8, 2026
  Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Dyne Therapeutics, Inc. (NASDAQ: DYN) both experienced significant declines in after-hours trading on September 8, 2026, with Sarepta down 11.4% and Dyne down 22%. The drop in Dyne shares followed the company’s announcement of a completed upsized public…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).